PharmAthene Completes Pharmacokinetic Studies Of Protexia(R); Program On Target For IND Filing In 2008

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that it has completed the initial pharmacokinetic (PK) testing of Protexia(R), the Company’s broad spectrum chemical nerve agent prophylaxis. The PK studies were conducted in two animal species and used the final pegylated version of rBChE for the first time.

More: continued here

Filed under: Bio-terrorism on March 14th, 2008